Nothing Special   »   [go: up one dir, main page]

Narisawa et al., 1998 - Google Patents

Increased shelf‐life of fosphenytoin: Solubilization of a degradant, phenytoin, through complexation with (SBE) 7m‐β‐CD

Narisawa et al., 1998

Document ID
8337540329268495235
Author
Narisawa S
Stella V
Publication year
Publication venue
Journal of pharmaceutical sciences

External Links

Snippet

Fosphenytoin, a water‐soluble prodrug of phenytoin, degrades primarily to phenytoin at pH values< 8 during long term storage; phenytoin readily precipitates when formed from fosphenytoin due to its limited aqueous solubility. The objective of this study was to develop …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48961—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the conjugate being in the form of a host-guest, i.e. being an inclusion complex, e.g. clathrate, cavitate, fullerene
    • A61K47/48969—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the conjugate being in the form of a host-guest, i.e. being an inclusion complex, e.g. clathrate, cavitate, fullerene inclusion being performed with a cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/30—Macromolecular compounds
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar, pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/06—Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds

Similar Documents

Publication Publication Date Title
US6133248A (en) Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
Jansook et al. Cyclodextrins: structure, physicochemical properties and pharmaceutical applications
Loftsson et al. Pharmacokinetics of cyclodextrins and drugs after oral and parenteral administration of drug/cyclodextrin complexes
Loftsson et al. Cyclodextrins as functional excipients: methods to enhance complexation efficiency
Narisawa et al. Increased shelf‐life of fosphenytoin: Solubilization of a degradant, phenytoin, through complexation with (SBE) 7m‐β‐CD
RU2615385C2 (en) Alkylated cyclodextrin compositions and processes for preparing and using the same related applications
JP3393253B2 (en) Highly water-soluble cyclodextrin derivatives and uses thereof
Zhao et al. Solubilization of fluasterone
Cirri et al. Simultaneous effect of cyclodextrin complexation, pH, and hydrophilic polymers on naproxen solubilization
Piel et al. Development of a non-surfactant parenteral formulation of miconazole by the use of cyclodextrins
US5773029A (en) High solubility multicomponent inclusion complexes consisting of an acidic drug, a cyclodextrin and a base
JP3509866B2 (en) Novel cyclodextrin derivative particularly usable for dissolving hydrophobic compounds such as drugs and method for preparing the same
Zia et al. Effect of alkyl chain length and degree of substitution on the complexation of sulfoalkyl ether β-cyclodextrins with steroids
EP0811386B1 (en) Method of selecting a salt for making an inclusion complex
AU2003205930B2 (en) Pharmaceutical composition
Puskás et al. Sulfobutylether-cyclodextrins: structure, degree of substitution and functional performance
WO2009016663A1 (en) Amphiphilic dextrin conjugates and their use in pharmaceutical formulations as complexing agents for hydrophobic drugs to improve the aqueous solubility and consequently the therapeutic efficacy of the complexed drugs
AU2003205930A1 (en) Pharmaceutical composition
Loftsson et al. Drug solubilization and stabilization by cyclodextrin drug carriers
Uzqueda et al. Characterization of complexes between naftifine and cyclodextrins in solution and in the solid state
Ran et al. Solubilization and preformulation studies on PG-300995 (an anti-HIV drug)
Stella Sbe7-β-CD, a New, Novel and Safe Polyanionic β-Cyclodextrin Derivative: Characterization And Biomedical Applications.
Sharapova et al. Screening of solubilization potential of various green excipients for case of hydrophobic antituberculous thioacetazone
Stella SBE7-B-CD, A NEW, NOVEL AND SAFE POLYANIONIC ẞ-CYCLODEXTRIN DERIVATIVE: BIOMEDICAL APPLICATIONS.
Kulkarni et al. Cyclodextrins and ternary complexes for solubility enhancement of poorly soluble drugs